Related references
Note: Only part of the references are listed.A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG
C. H. Smorenburg et al.
ANNALS OF ONCOLOGY (2014)
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer
J. Baselga et al.
ANNALS OF ONCOLOGY (2014)
Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: Results from the OMEGA study of the Dutch Breast Cancer Trialists' Group
M. E. Hamaker et al.
BREAST (2014)
Epidemiology of Breast Cancer
Kristen A. Ban et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2014)
Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a standard chemotherapy regimen: The CASA randomized trial
Diana Crivellari et al.
BREAST (2013)
Weekly combination of non-pegylated liposomal doxorubicin and taxane in first-line breast cancer: wALT trial (phase I-II)
M. S. Rosati et al.
ANNALS OF ONCOLOGY (2011)
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)
C. Rochlitz et al.
ANNALS OF ONCOLOGY (2011)
A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study
Patrizia Vici et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2011)
Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study
Emilio Alba et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial
Peter Schmid et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
A Phase II Randomized Crossover Study of Liposomal Doxorubicin Versus Weekly Docetaxel in the First-line Treatment of Women With Metastatic Breast Cancer
Denise A. Yardley et al.
CLINICAL BREAST CANCER (2009)
Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study
Joseph A. Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
2009 Updated Method Guidelines for Systematic Reviews in the Cochrane Back Review Group
Andrea D. Furlan et al.
SPINE (2009)
Metastatic breast cancer: The role of pegylated liposomal doxorubicin after conventional anthracyclines
Shailendra Verma et al.
CANCER TREATMENT REVIEWS (2008)
Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer:: the dark side of the moon?: A meta-analysis of the randomized trials
Emilio Bria et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer
MER O'Brien et al.
ANNALS OF ONCOLOGY (2004)
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer
AM Keller et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer
S Chan et al.
ANNALS OF ONCOLOGY (2004)
Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints
S Freels
STATISTICS IN MEDICINE (2004)
Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity
G Minotti et al.
PHARMACOLOGICAL REVIEWS (2004)
Congestive heart failure in patients treated with doxorubicin - A retrospective analysis of three trials
SM Swain et al.
CANCER (2003)
Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma
L Harris et al.
CANCER (2002)
Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer
G Batist et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
